Leonteq Securities AG’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-671
| Closed | -$27K | – | 1276 |
|
|
2026
Q1 | $27K | Sell |
671
-224
| -25% | -$4.83K | ﹤0.01% | 955 |
|
|
2025
Q4 | $22.5K | Sell |
895
-224
| -20% | -$5.25K | ﹤0.01% | 1073 |
|
|
2025
Q3 | $25.3K | Sell |
1,119
-102
| -8% | -$2.38K | ﹤0.01% | 1010 |
|
|
2025
Q2 | $21.1K | Hold |
1,221
| – | – | ﹤0.01% | 981 |
|
|
2025
Q1 | $26.8K | Sell |
1,221
-783
| -39% | -$21.6K | ﹤0.01% | 934 |
|
|
2024
Q4 | $63.9K | Sell |
2,004
-1,174
| -37% | -$35.3K | ﹤0.01% | 782 |
|
|
2024
Q3 | $91.7K | Buy |
3,178
+2,017
| +174% | +$74.7K | 0.01% | 638 |
|
|
2024
Q2 | $44.5K | Buy |
1,161
+1,050
| +946% | +$47.6K | ﹤0.01% | 786 |
|
|
2024
Q1 | $6.53K | Sell |
111
-219
| -66% | -$14K | ﹤0.01% | 1055 |
|
|
2023
Q4 | $19.8K | Sell |
330
-579
| -64% | -$29.4K | ﹤0.01% | 941 |
|
|
2023
Q3 | $34.6K | Buy |
+909
| New | +$39.9K | ﹤0.01% | 867 |
|
|
2023
Q2 | – | Sell |
-62
| Closed | -$4.09K | – | 1230 |
|
|
2023
Q1 | $4.09K | Buy |
+62
| New | +$3.58K | ﹤0.01% | 1119 |
|
|
2022
Q1 | – | Sell |
-2,223
| Closed | -$105K | – | 1247 |
|
|
2021
Q4 | $105K | Hold |
2,223
| – | – | ﹤0.01% | 765 |
|
|
2021
Q3 | $73.3K | Buy |
2,223
+1,563
| +237% | +$87.8K | ﹤0.01% | 779 |
|
|
2021
Q2 | $41.7K | Buy |
660
+20
| +3% | +$1.03K | ﹤0.01% | 863 |
|
|
2021
Q1 | $27.5K | Buy |
+640
| New | +$30.3K | ﹤0.01% | 844 |
|
Other funds holding APLS
Leonteq Securities AG's APLS Position: Q2 2026 in Review
Leonteq Securities AG sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 671 shares — an estimated $27K sold.
Leonteq Securities AG first reported a position in APLS in Q1 2021 and held it in 16 quarters. The position peaked at $105K in Q4 2021. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Leonteq Securities AG reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Leonteq Securities AG sold 671 Apellis Pharmaceuticals shares in Q2 2026, an estimated $27K.
- Leonteq Securities AG first reported a position in Apellis Pharmaceuticals in Q1 2021 and held it in 16 quarters.
- Leonteq Securities AG's Apellis Pharmaceuticals position peaked at $105K in Q4 2021.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.